Study type: Human research · Status: Evidence verified by machine against declared source
The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.
Critical care medicine · 2022
Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Abstract only: Open source record
Product or molecular entity relationships
- VIP: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Public plain-language summary
Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The study aims to determine whether Aviptadil (synthetic VIP) can improve survival and recovery in patients with COVID-19 respiratory failure compared with placebo and demonstrate biological effects in such patients.
Study design
A multicenter, placebo-controlled trial.
Participants or experimental system
A total of 196 patients with COVID-19 respiratory failure.
Study scale
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Intervention or exposure
The primary end point (alive and free from respiratory failure at day 60) did not reach statistical significance (odds ratio [OR], 1.6; 95% CI, 0.86–3.11) for patients treated with Aviptadil when controlling for baseline ventilation status as prespecified in the protocol.
Comparator
Participants were randomized 2:1 to receive 3 days of IV Aviptadil or placebo.
Outcomes examined
Subgroup analysis identified a statistically significant likelihood of achieving primary end point among those treated with high-flow nasal oxygen at baseline (p = 0.039).
Key findings
Vasoactive intestinal peptide (VIP) is shown in nonclinical studies to upregulate surfactant production, inhibit cytokine synthesis, prevent cytopathy, and block replication of the severe acute respiratory syndrome coronavirus 2 virus in pulmonary cells.
Limitations and uncertainty
Given the absence of drug-related SAEs and a suggestion (Fig. 2) that the short-term effect on RDR (P:F ratio) may narrow after cessation of infusion with Aviptadil, a longer duration of treatment should be considered in future trials.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.